Written Question · S3W-38010 · Session 3
Whether it plans to make available under the orphan drugs risk-sharing scheme orphan or ultra-orphan treatments rejected by the Scottish Me…
The question
To ask the Scottish Executive whether it plans to make available under the orphan drugs risk-sharing scheme orphan or ultra-orphan treatments rejected by the Scottish Medicines Consortium on the grounds of cost-effectiveness.
The answer
The National Services Division (NSD) Risk Share arrangements only include medicines recommended for use within NHS Scotland by the Scottish Medicines Consortium (SMC).
In appraising orphan medicines to treat rare diseases, the Scottish Medicines Consortium may, in addition to the standard assessment of clinical and
cost-effectiveness, apply modifiers which consider other additional factors. Subject to meeting certain criteria, this can facilitate acceptance of a medicine notwithstanding the economic evidence provided. Full details on SMC policies can be found on the SMC website:
http://www.scottishmedicines.org.uk/smc/3863.21.24.html.
NHS boards have arrangements in place to consider provision of medicines not recommended by the SMC, including high cost orphan medicines, for individual patients in certain circumstances.
In appraising orphan medicines to treat rare diseases, the Scottish Medicines Consortium may, in addition to the standard assessment of clinical and
cost-effectiveness, apply modifiers which consider other additional factors. Subject to meeting certain criteria, this can facilitate acceptance of a medicine notwithstanding the economic evidence provided. Full details on SMC policies can be found on the SMC website:
http://www.scottishmedicines.org.uk/smc/3863.21.24.html.
NHS boards have arrangements in place to consider provision of medicines not recommended by the SMC, including high cost orphan medicines, for individual patients in certain circumstances.
In the Official Report
No contribution in the Official Report cites S3W-38010 by reference.